Sanofi backs annual guidance as Dupixent sales surge over 40% in Q1

27 Apr 2023
firstwordpharma.com
Phase 1Phase 2Financial Statement
Headline results for the first quarter:
Prescription drug sales: €8.7 billion ($9.6 billion), up 4.9%
Overall revenue: €10.2 billion ($11.3 billion; forecasts of €10.5 billion), up 5.7%
Profit: €2 billion ($2.2 billion), down 0.7%
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
"We have started 2023 with strong results, delivering double-digit sales growth across our specialty care, vaccines and consumer healthcare businesses," remarked CEO Paul Hudson. The executive added "Dupixent continues its compelling performance and is on track to achieve its €10 billion sales objective for this year."
Other results:
Specialty care unit: €4.3 billion, up 20.2%
Dupixent: €2.3 billion, up 43.5%
Aubagio: €419 million, down 14.7%
Alprolix: €125 million, up 15.7%
Eloctate: €118 million, down 14.5%
General medicines unit: €3.3 billion, down 12.4%
Lantus: €447 million, down 33.4%
Toujeo: €289 million, up 5.5%
Praluent: €98 million, up 42%
Vaccines division: €1.2 billion, up 14.4%
Consumer healthcare: €1.5 billion, up 10.4%
Sales in China: €755 million, down 14% on a constant exchange rate (CER) basis
Looking ahead:
Sanofi continues to expect business earnings per share to grow in the low-single digits this year on a CER basis, excluding negative currency effects of between 5.5% and 6.5%. The company had previously flagged a negative currency impact in the range of 3.5% to 4.5%.
Pipeline updates:
Sanofi disclosed that development of the topical BTK inhibitorBTK inhibitor atuzabrutinib has been discontinued due to efficacy and sub-optimal pharmacokinetics from a Phase II study in patients with mild-to-moderate atopic dermatitis. The company added that a mid-stage trial of subcutaneous Sarclisa in adults with warm autoimmune haemolytic anaemia was also halted, citing preliminary results and portfolio prioritisation.
Meanwhile, a Phase I study evaluating the anti-TNFa/IL-6 antibody SAR444419 was discontinued based on the benefit/risk assessment.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.